Vigil Neuroscience (NASDAQ:VIGL) Receives Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research report report published on Tuesday,Benzinga reports. They currently have a $22.00 price objective on the stock.

Several other brokerages also recently commented on VIGL. Wedbush lifted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Guggenheim reduced their price objective on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Price Performance

Shares of Vigil Neuroscience stock opened at $2.47 on Tuesday. Vigil Neuroscience has a 1 year low of $2.08 and a 1 year high of $6.06. The company has a market capitalization of $100.97 million, a price-to-earnings ratio of -1.20 and a beta of 1.92. The business has a fifty day simple moving average of $3.40 and a two-hundred day simple moving average of $3.63.

Institutional Investors Weigh In On Vigil Neuroscience

Several institutional investors have recently made changes to their positions in VIGL. Acadian Asset Management LLC bought a new stake in Vigil Neuroscience during the second quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vigil Neuroscience in the 2nd quarter valued at approximately $87,000. Renaissance Technologies LLC lifted its holdings in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after acquiring an additional 11,536 shares during the period. Walleye Capital LLC boosted its position in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in Vigil Neuroscience in the third quarter valued at approximately $442,000. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.